✨ Free AI Report
Aytu BioPharma, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Aytu BioPharma, Inc.
Company Research

Aytu BioPharma, Inc.: Business Overview, Financials & Competitive Analysis

Aytu BioPharma, Inc. scores 4/10 on the AskCyborg Cyborg Score (Challenged). Early-stage specialty pharma with niche positioning in ADHD and pediatric therapeutics, facing execution challenges in clinical development and market commercialization. Aytu trades at historically depressed valuations with significant stock price volatility and limited financial scale. While the company has FDA recognitions and an established product portfolio in ADHD and.

What is Aytu BioPharma, Inc.'s industry? Aytu BioPharma, Inc. (aytubio.com) operates in Pharmaceuticals. AskCyborg classifies Aytu BioPharma, Inc. under Pharmaceuticals in its company registry.

Aytu BioPharma focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), inc...

4/ 10Challenged

Cyborg Score thesis

Early-stage specialty pharma with niche positioning in ADHD and pediatric therapeutics, facing execution challenges in clinical...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
3 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Aytu BioPharma, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Aytu BioPharma, Inc.

AskCyborg analysts argue the bull and bear cases for Aytu BioPharma, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Aytu BioPharma, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Aytu BioPharma, Inc. Overview

Pro stress-test →

Aytu BioPharma focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age. The company also maintains a pediatric portfolio addressing allergies and nutrient deficiencies.

Strategic Profile

Pro stress-test →

Aytu Biopharma is a specialty pharmaceutical company focusing on developing and commercializing novel therapeutics and consumer healthcare products. The company is pursuing clinical development of AR101, a protein kinase inhibitor candidate for rare genetic disorders, positioning itself in niche therapeutic areas with significant unmet medical needs.

Competitive Landscape

Pro stress-test →

Aytu competes in the crowded ADHD therapeutic market dominated by larger pharmaceutical players including Novartis (Ritalin), Shire/Takeda (Adhansia), and Johnson & Johnson (Concerta). In pediatric specialty products, competition includes established players like Pfizer and smaller specialty pharma firms. The company's differentiation rests on orally disintegrating tablet formulations and selective focus on pediatric populations.

Industry Context

Aytu BioPharma, Inc. operates in Pharmaceuticals.

Key facts

Founded: 2015 · Headquarters: Denver, Colorado

What the analysts stress-tested

The top findings that survived the multi-agent debate for Aytu BioPharma, Inc..

  • FDA granted Orphan Drug designation to Aytu BioPharma's AR101 for the treatment of vascular Ehlers-Danlos Syndrome
  • Cotempla XR-ODT is indicated for the treatment of ADHD in pediatric patients
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • FDA granted Orphan Drug designation to AR101 for vascular Ehlers-Danlos Syndrome treatment
  • Company changed its name from Aytu BioScience, Inc. to Aytu BioPharma, Inc. in March 2021
Get alerted when Aytu BioPharma, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

RitalinADHD treatment with methylphenidate→AdhansiaExtended-release ADHD medication→ConcertaOsmotic-release methylphenidate for ADHD→

Compare Aytu BioPharma, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Aytu BioPharma, Inc. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Aytu BioPharma, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Aytu BioPharma, Inc. and its top competitor on Cyborg Score”
“What did Aytu BioPharma, Inc. do this quarter?”
“Is Aytu BioPharma, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Aytu BioPharma, Inc. do?+
Aytu BioPharma focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), inc...
What is Aytu BioPharma, Inc.'s Cyborg Score?+
Aytu BioPharma, Inc. has a Cyborg Score of 4/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Aytu BioPharma, Inc.'s main competitors?+
Named competitors include Ritalin, Adhansia, Concerta. The full competitive landscape is in the AskCyborg report.
How can I get the full Aytu BioPharma, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Aytu BioPharma, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Aytu BioPharma, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.